We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's What Key Metrics Tell Us About Baxter (BAX) Q3 Earnings
Read MoreHide Full Article
Baxter International (BAX - Free Report) reported $2.84 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 5%. EPS of $0.69 for the same period compares to $0.80 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $2.87 billion, representing a surprise of -1.32%. The company delivered an EPS surprise of +15%, with the consensus EPS estimate being $0.60.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Sales- Pharmaceuticals- U.S.: $177 million versus the three-analyst average estimate of $183.65 million. The reported number represents a year-over-year change of -0.6%.
Net Sales- Pharmaceuticals- International: $455 million compared to the $455.99 million average estimate based on three analysts. The reported number represents a change of +11% year over year.
Net Sales- Healthcare Systems and Technologies- International: $196 million compared to the $203.02 million average estimate based on three analysts. The reported number represents a change of +0.5% year over year.
Net Sales- Care and Connectivity Solutions- International: $125 million versus the three-analyst average estimate of $128.48 million. The reported number represents a year-over-year change of +3.3%.
Net Sales- Pharmaceuticals: $632 million versus the five-analyst average estimate of $632.48 million. The reported number represents a year-over-year change of +7.5%.
Net Sales- Advanced Surgery: $306 million versus the five-analyst average estimate of $289.33 million. The reported number represents a year-over-year change of +12.5%.
Net Sales- Other: $101 million versus $91.79 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +494.1% change.
Net Sales- Front Line Care: $300 million versus the five-analyst average estimate of $302.84 million. The reported number represents a year-over-year change of +1.4%.
Net Sales- Infusion Therapies and Technologies: $1.02 billion versus $1.08 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -4.4% change.
Net Sales- Healthcare Systems and Technologies: $773 million compared to the $777.62 million average estimate based on five analysts. The reported number represents a change of +2.8% year over year.
Net Sales- Care and Connectivity Solutions: $473 million versus $474.59 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +3.7% change.
Net Sales- Medical Products and Therapies: $1.33 billion versus $1.37 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -1% change.
Shares of Baxter have returned -4% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's What Key Metrics Tell Us About Baxter (BAX) Q3 Earnings
Baxter International (BAX - Free Report) reported $2.84 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 5%. EPS of $0.69 for the same period compares to $0.80 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $2.87 billion, representing a surprise of -1.32%. The company delivered an EPS surprise of +15%, with the consensus EPS estimate being $0.60.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Baxter here>>>
Shares of Baxter have returned -4% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.